Cargando…

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study

BACKGROUND: Sirolimus has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). We wish to summarize our experience using sirolimus and its effectiveness in LAM patients. METHODS: We analyzed data from 98 patients who were diagnosed with definite or probable sporadic LAM based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhan, Yongzhong, Shen, Lisha, Xu, Wenshuai, Wu, Xiuxiu, Zhang, Weihong, Wang, Jun, Li, Xue, Yang, Yanli, Tian, Xinlun, Xu, Kai-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819088/ https://www.ncbi.nlm.nih.gov/pubmed/29458386 http://dx.doi.org/10.1186/s13023-018-0775-9

Ejemplares similares

Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
por: Hu, Siqi, et al.
Publicado: (2019)

Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study
por: Cheng, Chongsheng, et al.
Publicado: (2022)

Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM)
por: Shen, Lisha, et al.
Publicado: (2021)

The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis
por: Xu, Wenshuai, et al.
Publicado: (2021)

Recent advances in the management of lymphangioleiomyomatosis
por: Xu, Kai-Feng, et al.
Publicado: (2018)

Gene mutations in sporadic lymphangioleiomyomatosis and genotype–phenotype correlation analysis
por: Huang, Jiannan, et al.
Publicado: (2022)

Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis
por: Aghaeimeybodi, Fatemeh, et al.
Publicado: (2019)

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis
por: Steagall, Wendy K., et al.
Publicado: (2023)

The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
por: Gao, Nannan, et al.
Publicado: (2018)

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
por: Neurohr, Claus, et al.
Publicado: (2011)

Sirolimus in lymphangioleiomyomatosis: A case in point for research in ‘orphan’ diseases
por: Koul, Parvaiz A, et al.
Publicado: (2019)

Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
por: Namba, Masashi, et al.
Publicado: (2017)

Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus
por: Sakaue, Takahiko, et al.
Publicado: (2018)

Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier
por: Sonobe, Shoko, et al.
Publicado: (2018)

Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus
por: Ko, Yuki, et al.
Publicado: (2020)

Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study
por: Li, Xiangfeng, et al.
Publicado: (2020)

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations
por: Freitas, Carolina Salim Gonçalves, et al.
Publicado: (2015)

Pulmonary lymphangioleiomyomatosis presenting as spontaneous pneumothorax treated with sirolimus - A case report
por: Verma, Ajay Kumar, et al.
Publicado: (2018)

Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series
por: Zhou, Li, et al.
Publicado: (2018)

Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis
por: Huang, Yen-Lin, et al.
Publicado: (2021)

Expression profiles and potential functions of long noncoding RNAs and mRNAs in autoimmune pulmonary alveolar proteinosis patients
por: Yang, Yanli, et al.
Publicado: (2021)

Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis
por: Sakurai, Teiko, et al.
Publicado: (2021)

Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort
por: Gopalakrishnan, Vissagan, et al.
Publicado: (2018)

Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
por: Revilla-López, Eva, et al.
Publicado: (2021)

Characterization of CT scans of patients with Birt-Hogg-Dubé syndrome compared with those of Chinese patients with non-BHD diffuse cyst lung diseases
por: Xu, Wenshuai, et al.
Publicado: (2020)

Humoral response to inactivated SARS-CoV-2 vaccines in patients on sirolimus alone
por: Cheng, Chongsheng, et al.
Publicado: (2022)

Clinical and genetic characteristics of chinese patients with Birt-Hogg-Dubé syndrome
por: Liu, Yaping, et al.
Publicado: (2017)

The etiology of diffuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic
por: Cui, Han, et al.
Publicado: (2021)

Lymphangioleiomyomatosis: differential diagnosis and optimal management
por: Xu, Kai-Feng, et al.
Publicado: (2014)

Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma
por: Sun, Xuefeng, et al.
Publicado: (2016)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Usefulness of (99m)Tc-ASC lymphoscintigraphy and SPECT/CT in the evaluation of rare lymphatic disorders: Gorham–Stout disease, lymphangioma, and lymphangioleiomyomatosis
por: Hou, Guozhu, et al.
Publicado: (2020)

(68)Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with (99m)TC-ASC lymphoscintigraphy: a prospective study
por: Hou, Guozhu, et al.
Publicado: (2021)

Lung function and systemic inflammation associated with short-term air pollution exposure in chronic obstructive pulmonary disease patients in Beijing, China
por: Gao, Nannan, et al.
Publicado: (2020)

Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome
por: Liu, Shuang, et al.
Publicado: (2019)

Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014)

Lymphangioleiomyomatosis (LAM)
Publicado: (2017)

Dynamic Observation of Autophagy and Transcriptome Profiles in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis
por: Wang, Yani, et al.
Publicado: (2021)

Clinical characteristics and genetic spectrum of 26 individuals of Chinese origin with primary ciliary dyskinesia
por: Zhao, Xinyue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dij09ul72u6lfsah3mld0ceoo5